Tecartus will require authorization for commercial members effective August and September 2020

We're adding authorization requirements for Tecartus (brexucabtagene autoleucel), HCPCS code J9999, a specialty drug covered under the medical benefit, for the following members:

How to submit authorization requests

Submit authorization requests through NovoLogix. It offers real-time status checks and immediate approvals for certain medications.

To learn how to submit requests through NovoLogix, do the following from within this website:

More about the authorization requirements

These authorization requirements apply only to groups that currently participate in the standard commercial Medical Drug Prior Authorization Program for drugs administered under the medical benefit. These changes don't apply to members covered by the Federal Employee Program® Service Benefit Plan.

Authorization isn't a guarantee of payment. Health care practitioners need to verify eligibility and benefits for members.

List of requirements

For a list of requirements related to drugs covered under the medical benefit, please see the Blue Cross and BCN utilization management medical drug list for Blue Cross PPO (commercial) and BCN HMO (commercial) members (PDF) document, which is available from these pages of this website:

We'll update the requirements list with this information prior to each effective date.

Posted: August 2020
Lines of business: Blue Cross Blue Shield of Michigan and Blue Care Network